Amid the ongoing opioid crisis, the need for non-opioid pain management solutions is increasing. As a provider of pre- and post-surgical non-opioid pain management solutions, the relatively unknown company featured in today’s article has seen its stock driven higher over the past year – and with the FDA having just approved the expanded label of its non-opioid painkiller for managing severe post-surgical pain in pediatric patients (for whom no such product has existed until now), its stock could be poised to move even higher. For more, CLICK HERE.
A Recently Approved Label Expansion Could Expand This Pain Management Stock’s Horizons
Tags:Approved Label ExpansionBiotechBiotech SectorClinical ResearchFDA ApprovalInvestingInvestmentOpioid CrisisPain Management SolutionsUnder the Radar Biotechs